Author ORCID Identifier
psoriasis, Guselkumab, Tremfya, Lentigines
Dermatology | Medicine and Health Sciences | Other Pharmacy and Pharmaceutical Sciences
Eruptive lentigines in the area of resolving psoriatic plaques has been well documented in the literature following successful treatment with multiple therapies. This is historically associated with light treatment but has been expanded to include other therapies such as anti-tumor necrosis factor therapies and, more recently, some biologics5. Guselkumab (Tremfya) is an IgG1λ monoclonal antibody used in the treatment of plaque psoriasis with only one case of eruptive lentigines confined to resolving psoriatic plaques (ELRP) noted as a side effect. We present the second such case of ELRP associated with successful treatment of plaque psoriasis with Guselkumab, as it is important to document potential side effects of medications regardless of their severity.
Kilgore JR, Curry JC, Cook SE.
Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab.
Marshall J Med.